FGI-106

Name: FGI-106
Brand: TargetMol
SKU: T11281
Rating: 4.5 (1 reviews)

还可以

产品编号 T11281Cas号 501081-38-5

FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

FGI-106

还可以

产品编号 T11281Cas号 501081-38-5

规格	价格	库存
25 mg	¥ 17,200	1-2周
50 mg	¥ 22,800	1-2周
100 mg	¥ 29,500	1-2周

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

联系我们获取更多批次信息

资源下载

产品操作手册

产品介绍

生物活性

产品描述	FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.
靶点活性	HIV-1:150 nM , EBOV:（EC50）100 nM , DENV: 400-900 nM , HCV: 200 nM , Rift Valley virus: 800 nM
体外活性	In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses.Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM.
体内活性	FGI-106 (0.1-5 mg/kg;?intraperitoneal injection;?treatments on days 2 and 5;?C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner.